1. Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function 
Suwebatu T. Odunsi–Shiyanbade, Michael Camilleri, Sanna McKinzie, Duane Burton, Paula Carlson, Irene A. Busciglio, Jesse Lamsam, Ravinder Singh, Alan R. Zinsmeister 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 2, Pages e5 (February 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Effects of Na CDC on colonic transit (GC) at 24 and 48 hours, and stool form and frequency. Data show least square means ± standard error of the mean. Note that there is an overall acceleration of colonic transit, and this is significantly greater with the 1000-mg dose of Na CDC (P < vs placebo) relative to the 500-mg dose (P < .01 vs placebo), particularly evident with the transit data at 24 hours (overall P < .05, 1000 vs 500 mg). Note also that the acceleration of colonic transit is associated with an increase in stool frequency (P < .001) and a more liquid consistency stool (P < .0001).
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Effects of placebo or colesevelam on overall colonic transit at 24 hours in individual patients. Note that 7 of 12 participants in the colesevelam arm had reduced colonic transit by more than 0.7. The lines link the transit results at baseline and posttreatment.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Effects of colesevelam and placebo on ascending colon emptying t1/2 in relation to the rank of baseline fasting serum 7αC4 level. Note that the relationship between baseline fasting serum 7αC4 level and ascending colon emptying times was positive in patients on colesevelam treatment, but negative in patients on placebo, implying that treatment effects were enhanced by 7αC4 on active drug, but not on placebo. Solid lines represent the regression lines (predicted value for a given X-axis value), dashed lines represent the 95% confidence limits for the regression lines, and the dotted lines represent the prediction or tolerance limits for the regression lines.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

5. Supplementary Figure 1
Study flow chart and demographics of participants in CDC study.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

6. Supplementary Figure 2
Study flow chart and demographics of participants in the colesevelam study.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

7. Supplementary Figure 3
Comparison of baseline serum 7αC4 level in the IBS-D patients randomized to placebo and colesevelam groups.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

8. Supplementary Figure 4
Comparison of serum FGF-19 level between healthy controls and IBS-D patients.
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

9. Supplementary Figure 5
Relationship between serum 7αC4 and FGF-19 levels. The right plot shows the ranks of 7αC4 on the Y-axis and the regression line based on the ranks of 7αC4 versus serum FGF-19 level. The Spearman rank correlation was used to estimate the strength of the association (rs = −0.414; P = .044).
Clinical Gastroenterology and Hepatology 2010 8, e5DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions